Search results for: cmt
CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
Schwann Cell-Targeted Peptide-LNPs for Delivery of siRNA Against PMP22 in CMT1A
With combined support totaling $102,968 from CMTA, Shark Tooth Bio, and the National Research Council...
Blood–Brain Barrier-Crossing Conjugates for Treating CMT
With CMTA support of $54,051, researchers led by Yizhou Dong, PhD, at the Icahn School...
Preliminary Characterization of STEP Platform for Delivery of Genome Editing Therapy for CMT
With CMTA support of $66,000, researchers led by Jiangbing Zhou, PhD, at Yale University are...
CMTA Appoints Wendy Arnone as Board Chair
CMTA has appointed Wendy Arnone as board chair, succeeding Gilles Bouchard, who has led the board since 2016 and will continue serving as a board member. Arnone brings decades of executive healthcare leadership experience and a clinical background as a registered nurse, positioning her to guide CMTA’s continued investment in research and drug development for CMT.
CMTA Center of Excellence at Johns Hopkins All Children’s Hospital
Matias Sebastian Lopez Chacon, MD, is a pediatric neurologist and neuromuscular specialist at Johns Hopkins All...
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A – (CANADA ONLY)
About this Study The purpose of this study is to characterize the safety, tolerability, and...
CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update
New Phase 2a CMT trial results are in. NMD Pharma shares details.
Get the latest CMT research and care news
Stay connected with CMTA Subscribe to receive clinical information, research updates, and invitations to connect...
CMTA Invests $100,000 in EverTree Bio to Support Cutting-Edge Therapeutic Research for CMT1A
CMTA announces a $100,000 investment in EverTree Bio to support continued development of an early-stage therapeutic program for CMT1A. The investment builds on early testing through the CMTA Preclinical Toolbox and reflects CMTA’s role in keeping strong CMT-focused research moving when it might otherwise stall.
